CIBC analyst Kevin Chiang downgrades NFI Group (TSX:NFI) from Neutral to Underperformer and announces C$8.5 price target.
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration Of Ixoberogene Soroparvovec At The 2023 ARVO Annual Meeting
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present an
